Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × melflufen × Clear all

Phase

Phase 3 2 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Renal Insufficiency 1 Multiple Myeloma 1

Interventions

Cyclophosphamide 166 Docetaxel 153 Bevacizumab 153 Carboplatin 145 Gemcitabine 144 Cisplatin 142 pembrolizumab 141 Radiotherapy 134 Paclitaxel 130 Capecitabine 121 Rituximab 115 Oxaliplatin 103 Fluorouracil 102 Nivolumab 90 Irinotecan 85 Doxorubicin 85 Leucovorin 81 Dexamethasone 81 Pemetrexed 80 fludarabine 74 fludarabine phosphate 72 Bortezomib 68 Etoposide 66 Erlotinib Hydrochloride 66 Cetuximab 64 Methotrexate 58 Trastuzumab 56 Cytarabine 54 Lenalidomide 49 Everolimus 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03639610 2023-03-10

BRIDGE

Oncopeptides AB

Phase 2 Terminated

35 enrolled 33 charts

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon ⚡